Pharmacokinetic and clinical evaluation of moxalactam in infants and children.
37 patients ranging in age from 9 months to 14 years, with various infections, were treated with moxalactam. The pharmacokinetics of the drug were studied in 18 patients. The mean plasma concentration 1 h after a 25 mg/kg intravenous dose was 41.4 micrograms/ml +/- 15.6 SD, the half-life was 1.5 h +/- 0.4 SD and the mean Vd was 550 ml/kg +/- 239 SD. The total body clearance of moxalactam was 4.1 ml/min/kg +/- 1.5 SD and the mean renal clearance 4.5 ml/min/kg +/- 2.8 SD. Between 52 and 107% of the administered dose was recovered in the urine within 8 h after administration. The pharmacokinetics after the first and multiple doses of moxalactam were similar, indicating no accumulation of the drug with repeated administration. The clinical response was adequate in 35 of 37 patients. Moxalactam was well tolerated and only minor and transient hematological abnormalities were observed.
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000378:metabolism* / Q000627:therapeutic use; D001170:Arthritis, Infectious / Q000188:drug therapy / Q000378:metabolism; D002481:Cellulitis / Q000188:drug therapy / Q000378:metabolism; D002511:Cephalosporins / Q000378:metabolism*; D002513:Cephamycins / Q000378:metabolism* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006207:Half-Life; D006801:Humans; D007223:Infant; D007700:Kinetics; D008199:Lymphadenitis / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D009070:Moxalactam; D010019:Osteomyelitis / Q000188:drug therapy / Q000378:metabolism; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy / Q000378:metabolism
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002513:Cephamycins; D009070:Moxalactam